Israel - englanti - Ministry of Health

inovamed pharma ltd, israel - entecavir as monohydrate - film coated tablets - entecavir as monohydrate 1 mg - entecavir - entecavir inovamed is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: - compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. - decompensated liver disease.

Israel - englanti - Ministry of Health

trima israel pharmaceutical products maabarot ltd - entecavir as monohydrate - film coated tablets - entecavir as monohydrate 0.5 mg - entecavir - entecavir - trima is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: - compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. - decompensated liver disease.

Israel - englanti - Ministry of Health

trima israel pharmaceutical products maabarot ltd - entecavir as monohydrate - film coated tablets - entecavir as monohydrate 1 mg - entecavir - entecavir - trima is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: - compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. - decompensated liver disease.

Kanada - englanti - Health Canada

pharmascience inc - entecavir - tablet - 0.5mg - entecavir 0.5mg - nucleosides and nucleotides

Kanada - englanti - Health Canada

pharmascience inc - entecavir - tablet - 1mg - entecavir 1mg - nucleosides and nucleotides

Kanada - englanti - Health Canada

mint pharmaceuticals inc - entecavir (entecavir monohydrate) - tablet - 0.5mg - entecavir (entecavir monohydrate) 0.5mg - nucleosides and nucleotides

Kanada - englanti - Health Canada

strides pharma canada inc - entecavir (entecavir monohydrate) - tablet - 0.5mg - entecavir (entecavir monohydrate) 0.5mg - nucleosides and nucleotides

Australia - englanti - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - entecavir, quantity: 0.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; lactose monohydrate; microcrystalline cellulose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - entecavir is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation.,this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamivudine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease

Australia - englanti - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - entecavir, quantity: 1 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; crospovidone; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - entecavir is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation.,this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamivudine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease

Australia - englanti - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - entecavir, quantity: 1 mg - tablet, film coated - excipient ingredients: crospovidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - entecavir is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation.,this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamivudine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease